Search Videos and More

Showing 1 - 12 of 20 results

Previous| 1 | 2 |Next


Antibody-Drug Conjugates: A Cancer Therapy Revolution News

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients
New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing News

New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.
Institute Research Shines at Society of Gynecologic Oncology Annual Meeting News

Institute Research Shines at Society of Gynecologic Oncology Annual Meeting

Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.
Seeking Signs of Synergy: The Origins of PARP and PI3K Inhibitors News

Seeking Signs of Synergy: The Origins of PARP and PI3K Inhibitors

Pairing multiple drugs together to synergistically destroy a patient's tumor has become a common approach to cancer treatment
Therapy for Small, HER2-positive Breast Tumors Continues to Be Highly Effective After 10 Years, Study Finds News

Therapy for Small, HER2-positive Breast Tumors Continues to Be Highly Effective After 10 Years, Study Finds

Follow-up results of a clinical trial that defined the standard treatment for patients with small, HER2-positive breast cancer that hasn't spread to the lymph nodes reinforce the long-term effectiveness of the therapy.
Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer News

Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients with Ovarian Cancer

A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 14 for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses folate receptor alpha.
Advancing New Treatments for Uncommon Cancer Subtypes News

Advancing New Treatments for Uncommon Cancer Subtypes

The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.
Combination Therapy Produces Encouraging Results in Patients with Gynecologic Cancers with Distinct Genetic Mutations News

Combination Therapy Produces Encouraging Results in Patients with Gynecologic Cancers with Distinct Genetic Mutations

A two-drug therapy that sets certain cancer cells up for failure and then finishes them off showed encouraging activity in a clinical trial of patients with gynecologic cancers that harbor mutations in a key gene, Dana-Farber investigators reported at the Society for Gynecologic Oncology (SGO) Annual Meeting in March.
2022 Society of Gynecologic Oncology (SGO) Symposium

2022 Society of Gynecologic Oncology (SGO)

DFCI Faculty share highlights from the Society of Gynecologic Oncology Annual Meeting on Women's Cancers held on March 18-21, 2022, in Phoenix, AZ and online.
Panos Konstantinopoulos, MD, PhD Shares Results of a Phase 2 Endometrial Cancer Study at 2022 SGO Video

Panos Konstantinopoulos, MD, PhD Shares Results of a Phase 2 Endometrial Cancer Study at 2022 SGO

Panos Konstantinopoulos, MD, PhD shares results of a phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or persistent endometrial cancer at the 2022 Society for Gynecologic Oncology Annual Meeting.
Ursula Matulonis, MD Shares Results of the SORAYA Study Video

Ursula Matulonis, MD Shares Results of the SORAYA Study

Ursula Matulonis, MD presented results of the SORAYA study at the 2022 Society for Gynecologic Oncology Annual Meeting.
Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show News

Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show

In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments. Results from this study were presented by Dana-Farber's Ursula Matulonis, MD during a plenary session at the SGO 2022 Annual Meeting.

Showing 1 - 12 of 20 results

Previous| 1 | 2 |Next